SCHEMBL7613340

SCHEMBL7613340

CCOC(=O)c1cnc2c(c1)/C(=C\Nc1cc(-c3ccccc3)nn1C)C(=O)N2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 2/20 0.40
JMJD6 Q6NYC1 1/20 0.40
MDM2 Q00987 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
GPR142 Q7Z601 1/20 0.39
MAPT P10636 5/20 0.39
MEN1 O00255 2/20 0.39
GAA P10253 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7613347 1.00 SMN1; SMN2 (0.40) SMN1; SMN2POLBJMJD6MDM2RAB9A
SCHEMBL7606283 0.83 JAK3 (0.41) POLBRAB9AMAPTNTRK1
SCHEMBL7606291 0.83 JAK3 (0.41) POLBRAB9AMAPTNTRK1
SCHEMBL7609675 0.81 NTRK1 (0.46) POLBRAB9AMAPTCCNA2CDK2
SCHEMBL7609671 0.81 NTRK1 (0.46) POLBRAB9AMAPTCCNA2CDK2
SCHEMBL7607104 0.80 ALDH1A1 (0.38) SMN1; SMN2JMJD6MDM2RAB9ANPC1
SCHEMBL7607108 0.80 ALDH1A1 (0.38) SMN1; SMN2JMJD6MDM2RAB9ANPC1
SCHEMBL5873824 0.78 ALDH1A1 (0.37) POLBMDM2MAPTKMT2AALDH1A1
SCHEMBL5873821 0.78 ALDH1A1 (0.37) POLBMDM2MAPTKMT2AALDH1A1
SCHEMBL5873926 0.78 P2RY12 (0.45) SMN1; SMN2POLBRAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX SMN1; SMN2 4854/4885POLB 3589/4885JMJD6 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.